New Chairman for Redx

Redx Pharma, the Cheshire-headquartered research and development company focused on cancer, immunology and infection, has brought in a new chairman. The move to appoint Iain Ross comes a month after the Alderley Park business revealed plans to cut 80 jobs as part of a major restructuring.

Dr Neil Murray, Chief Executive Officer of Redx Pharma, commented on Iain’s appointment, “I am delighted to welcome Iain Ross to Redx Pharma as Chairman of the Board. His extensive experience in the life science sector makes him the ideal candidate to take on this role. I am confident that under his stewardship the Company will deliver shareholder value as we transition into a clinical-stage research and development company with a focus on cancer, immunology and infection.”

Iain Ross, incoming Chairman of Redx Pharma, commented on his appointment, “Redx Pharma is a business of the highest quality that has discovered high value assets in cancer, immunology and infection and the opportunity to be part of progressing these promising assets through the clinic was instantly appealing. I look forward to working with the Board to realise the value of our best-in-class assets, alongside several other promising assets in the Company’s pipeline.”

See more at


This website makes reference to the previous rounds of investments made by Seneca Partners on behalf of certain investors within the Seneca EIS Portfolio Service. The rationale for the investment may no longer be valid. Under no circumstances should you take this information as a recommendation by Seneca Partners for you to invest in the Service or in any of the companies listed above.

Get in touch

For administrative and shareholder queries, please contact the Seneca EIS Team

For sales or other general queries, please contact the Seneca EIS Team or LGBR Capital